ArticleEvidence-based complementary and alternative medicine : eCAM2012
Effect of keishibukuryogan on endothelial function in patients with at least one component of the diagnostic criteria for metabolic syndrome: a controlled clinical trial with crossover design.
Article in Evidence-based complementary and alternative medicine : eCAM, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Natural products for managing metabolic syndrome: a scoping review.Frontiers in pharmacology · 2024Article
- The Multiple Pharmacologic Functions and Mechanisms of Action of Guizhi Fuling Formulation.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Systematic Review of Polyherbal Combinations Used in Metabolic Syndrome.Frontiers in pharmacology · 2021Review
- A Review on the Mechanism and Application of Keishibukuryogan.Frontiers in nutrition · 2021Review
- Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment.Journal of immunology research · 2021Review
- Role of Blood Stasis Syndrome of Kampo Medicine in the Early Pathogenic Stage of Atherosclerosis: A Retrospective Cross-Sectional Study.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Article
- Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract.BMC complementary medicine and therapies · 2020Article
- Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches.Scientific reports · 2019Article
- The Effects of Guizhi Fuling Capsule Drug Serum on Uterine Leiomyoma Cells and Its Mechanism.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Herbal Medicines for Treating Metabolic Syndrome: A Systematic Review of Randomized Controlled Trials.Evidence-based complementary and alternative medicine : eCAM · 2016Review
- What has been overlooked on study of Chinese materia medica in the West?Chinese journal of integrative medicine · 2015Review
- Effect of keishibukuryogan on genetic and dietary obesity models.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Effects of kampo formulas on the progression of hypercholesterolemia and Fatty liver induced by high-cholesterol diet in rats.Yonago acta medica · 2014Article
- Blood stasis syndrome in Japan and its molecular biological analysis.Chinese journal of integrative medicine · 2014Article
- The traditional kampo medicine tokishakuyakusan increases ocular blood flow in healthy subjects.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Efficacy of kampo medicine in treating atopic dermatitis: an overview.Evidence-based complementary and alternative medicine : eCAM · 2013Review
- Effectiveness of keishibukuryogan on chronic-stage lichenification associated with atopic dermatitis.ISRN dermatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the effect of keishibukuryogan (KBG; Guizhi-Fuling-Wan), a traditional Japanese (Kampo) formula, on endothelial function assessed by reactive hyperemia peripheral arterial tonometry (Endo-PAT2000) in patients with metabolic syndrome-related factors by controlled clinical trial with crossover design. Ninety-two patients were assigned to group A (first KBG-treatment period, then control period; each lasting 4 weeks, with about one-year interval) or group B (first control, then KBG-treatment). In forty-nine (27, group A; 22, group B) patients completing all tests, the mean value of the natural logarithmic-scaled reactive hyperemia index (L_RHI) increased and those of serum nonesterified fatty acid (NEFA), malondialdehyde, and soluble vascular cell adhesion molecule 1 decreased significantly during the KBG-treatment period, but not during the control period, and 4-week changes of L_RHI, NEFA, and malondialdehyde between the 2 periods showed significance. These results suggest that KBG has beneficial effect on endothelial function in patients with metabolic syndrome-related factors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.